for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CareDx Inc

CDNA.OQ

Latest Trade

85.43USD

Change

-2.23(-2.54%)

Volume

396,247

Today's Range

85.25

 - 

88.61

52 Week Range

13.19

 - 

99.70

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
87.66
Open
87.69
Volume
396,247
3M AVG Volume
13.58
Today's High
88.61
Today's Low
85.25
52 Week High
99.70
52 Week Low
13.19
Shares Out (MIL)
49.26
Market Cap (MIL)
4,317.89
Forward P/E
547.88
Dividend (Yield %)
--

Next Event

CareDx Inc Annual Shareholders Meeting

Latest Developments

More

Caredx Says Public Offering Of 1.92 mln Common Shares Priced At $91 per Share

CareDx Announces Proposed Public Offering Of Common Stock

Caredx Sees Q4 2020 Revenue $58.4 Million To $58.6 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CareDx Inc

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Industry

Healthcare Facilities

Contact Info

1 Tower Place, 9Th Floor

SOUTH SAN FRANCISCO, CA

94080

United States

+1.415.2872300

https://www.caredx.com/

Executive Leadership

Peter Maag

Executive Chairman of the Board of Directors

Reginald Seeto

President, Chief Executive Officer, Director

Marcel Konrad

Interim Chief Financial Officer

Sasha King

Chief Marketing Officer

Michael D. Goldberg

Lead Independent Director

Key Stats

1.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.1K

2019

0.1K

2020(E)

0.2K
EPS (USD)

2017

-0.690

2018

-0.150

2019

0.100

2020(E)

0.160
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.49
Price To Book (MRQ)
16.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-9.86
Return on Equity (TTM)
-8.02

Latest News

Latest News

BRIEF-New Kidney360 Publication Highlights Caredx’S Allosure Is Differentiated As The Dd-Cfdna Test Of Choice

* NEW KIDNEY360 PUBLICATION HIGHLIGHTS CAREDX’S ALLOSURE IS DIFFERENTIATED AS THE DD-CFDNA TEST OF CHOICE

BRIEF-Caredx Files Preliminary Prospectus Supplement Related To $100 Mln Common Stock Offering - SEC Filing

* CAREDX FILES PRELIMINARY PROSPECTUS SUPPLEMENT RELATED TO $100 MILLION COMMON STOCK OFFERING - SEC FILING Source : (https://bit.ly/37nRhjC) Further company coverage:

BRIEF-Caredx's Alloseq Tx 17 Awarded CE Mark Approval

* CAREDX'S ALLOSEQ TX 17 AWARDED CE MARK APPROVAL Source text for Eikon: Further company coverage:

BRIEF-Caredx And Veracyte Announce Partnership For Transplant Rejection Testing On Ncounter System

* CAREDX AND VERACYTE ANNOUNCE EXCLUSIVE PARTNERSHIP FOR TRANSPLANT REJECTION TESTING ON NCOUNTER SYSTEM

BRIEF-CareDx Says Withdrew Previously Issued Full Year 2020 Revenue Guidance

* CAREDX REPORTS PRELIMINARY FIRST QUARTER 2020 REVENUE AND PROVIDES BUSINESS UPDATE IN RESPONSE TO COVID-19 PANDEMIC

BRIEF-CareDx Posts Q4 Non-GAAP Earnings Per Share Of $0.04

* Q4 REVENUE $35.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $35.8 MILLION

BRIEF-Caredx's Patent Rights Upheld By Delaware Court

* CAREDX - COURT RECOMMENDED DENIAL OF NATERA INC.'S & EUROFINS VIRACOR INC.'S MOTIONS TO DISMISS CAREDX'S PATENT INFRINGEMENT COMPLAINTS AGAINST THEM

IN BRIEF: Judge won’t dismiss patent suit over Natera’s kidney transplant rejection test

A patent infringement lawsuit by Stanford University and licensee CareDx Inc against genetic testing company Natera Inc survived a motion to dismiss on Tuesday in U.S. District Court in Delaware.

CareDx adds false advertising claims to patent dispute with Natera

Medical diagnostics company CareDx Inc on Wednesday escalated a legal battle with rival Natera Inc over kidney transplant technology, adding false advertising claims in a new lawsuit to what began as a patent dispute.

BRIEF-CareDx Reports Q1 Loss Per Share $0.30

* FOR FULL YEAR 2018, CAREDX EXPECTS REVENUE TO BE IN RANGE OF $64 MILLION TO $66 MILLION Source text for Eikon: Further company coverage:

BRIEF-Caredx Inc Enters Into A License And Commercialization Agreement With Illumina

* CAREDX INC - ON MAY 4, 2018, CO ENTERED INTO A LICENSE AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA, INC - SEC FILING

BRIEF-Caredx Enters Into A Credit Agreement And Guaranty - SEC Filing

* CAREDX SAYS ON APRIL 17 ENTERED INTO A CREDIT AGREEMENT AND GUARANTY - SEC FILING

BRIEF-Caredx Launches Heartcare For Heart Transplant Recipients

* ANNOUNCED LAUNCH OF HEARTCARE, A COMPREHENSIVE REJECTION SURVEILLANCE SOLUTION FOR HEART TRANSPLANT RECIPIENTS Source text for Eikon: Further company coverage:

BRIEF-CareDx Q4 Non-Gaap Loss Per Share $0.09

* FY2018 REVENUE VIEW $61.5 MILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Caredx - Entered Binding Commitment With Perceptive Advisors For Term Loan Of Between $15 Mln And $35 Mln

* CAREDX - ENTERED BINDING COMMITMENT WITH PERCEPTIVE ADVISORS FOR A TERM LOAN OF BETWEEN $15 MILLION AND $35 MILLION

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up